The efficacy of trimethylpsoralen bath PUVA and UVB TL01 were compared in chronic plaque psoriasis. Patients were randomly assigned to receive UVB TL01 on one side and bath PUVA on the contra-lateral side. Altogether 17 patients received treatments and 15 completed the trial. The decrease in the PASI score was greater with UVB TL01 than PUVA. At the end of the treatment period, the difference was highly significant (pv0.001). The difference was already significant at week 3 (p~0.014). The relative median decrease in the PASI score was 77% (24 -100%) with UVB and 45% (8 -100%) with PUVA. The median cumulative UVB dose was 39.92 (range 13.95 -81.56) J/ cm 2 and the corresponding UVA dose was 8.06 (range 3.31 -12.51) J/cm 2 . All patients relapsed within 4 months. Narrowband UVB improved psoriasis clinically and statistically more efficiently than trimethylpsoralen bath PUVA, and UVB was better tolerated.
Studies comparing the efficacy of oral or bath delivery of 8-methoxypsoralen (8-MOP) plus ultraviolet A (UVA) and narrowband ultraviolet B (UVB) have given contradictory results (1, 2) . Only in one study has 4,5',8 -trimethylpsoralen (trioxysalen, TMP) bath PUVA been compared with narrowband UVB phototherapy (3) . The greater efficacy of narrowband UVB (wavelength range 309 -313 nm) over broadband UVB has been confirmed in several studies (4 -6) . In Europe the shift from broadband UVB TL12 phototherapy to narrowband UVB TL01 is now nearly complete. At the same time, it is considered prudent to retain systemic 8-MOP PUVA as a reserve for the treatment of severe psoriasis (7) .
PUVA is an acronym for psoralen plus ultraviolet A therapy. Psoralens are photosensitizers, which can be administered orally or topically using baths or creams. TMP bath PUVA was introduced in 1976, and its efficacy was confirmed in further studies (8 -11) . The bath delivery avoids most of the side-effects of oral administration, such as nausea (12) . Extended use of oral 8-MOP PUVA increases the risk of skin cancer, whereas TMP bath PUVA is regarded as relatively safe (13, 14) . In the short term, however, topically administered TMP is highly phototoxic. Its erythemal response reaches a maximum as late as at 96 -120 h. The photosensitivity after a single bath vanishes within 24 h (15, 16) . The objective of our trial was to compare the efficacy of UVB TL01 and TMP bath PUVA as treatments for plaque-type psoriasis.
PATIENTS AND METHODS
The Ethical Committee of the Pä ijä t-Hä me Hospital District approved the study protocol. Volunteering patients gave written consent for their participation in the study. TMP bath PUVA and UVB TL01 treatments were strictly implemented as mono-therapy. The study conformed to the CONSORT statement (17) .
Patients
Eligibility criteria. Psoriasis patients over 18 years of age, suitable for and in need of phototherapy were eligible for the study. All patients had to live in the Päijä t-Häme Hospital District. Their psoriasis had to be chronic over 2 years of duration, symmetric and predominantly of plaque type. A need for phototherapy had to be noted in the referral arriving in the Department of Dermatology from a general practitioner or private dermatologist. Phototolerant skin phototypes II -IV could be included (18) . The washout period was 2 months for all systemic psoriasis treatments or phototherapy, and 2 weeks for topical anti-psoriasis treatments.
Altogether 18 volunteer adult patients with chronic predominantly plaque-type psoriasis were enrolled and randomized in the study from September 2001 to March 2002 (Fig. 1) . The severity of their psoriasis ranged from mild to severe. The last follow-up visit was in August 2002. One patient allocated to receive UVB on the left side withdrew from the study immediately after randomization, before any interventions or assessments were performed. The withdrawal was due to the patient's busy schedule. As no data were received, he was excluded from the analyses.
All remaining 17 patients, 4 females and 13 males, started interventions and were included in the analyses. Their mean age was 46¡12 years (Table I ). The median MED value was 0.56 J/cm 2 (range 0. 28 -0.8 J/cm at that point showing a 67% decrease in PASI score with UVB and 17% decrease with PUVA.
Phototesting. The minimal erythema dose (MED) and minimal phototoxic dose (MPD) were assessed for all participants at the onset of the study using geometric dose series increasing by a factor d2, ranging from 0.2 to 1.12 J/cm 2 for UVB TL01 and from 0.05 to 0.28 J/cm 2 for UVA. The MPD testing, read at 72 h, was performed as described earlier (15) . The MED and MPD were defined as doses producing a faint, just perceptible erythema with three visible corners. For phototesting, a Waldmann 801K panel (Waldmann, Schwenningen, Germany) was used, equipped with six UVA tubes (Philips Performance Sunlamp 40W) and four UVB TL01 tubes (Philips TL20W/01RS). The irradiance of the test tubes was calibrated.
Sample size and random allocation. The study was implemented as a controlled half-side, single (investigator)-blinded comparison study, where the randomization determined the side of the UVB TL01 treatment. TMP bath PUVA was given on the contra-lateral side. In order for 80% power to detect 10% difference in the psoriasis area and severity index (PASI) score, which is suggested to be clinically significant at the 5% significance level, a minimum of 12 patients were required in the study. Treatment allocation, performed by one of the authors (TK) not involved in the patient evaluations, was based on an automatically computed random number table, from where the initial point was randomly taken. Treatments were assigned on the basis of sealed envelopes distributed to patients in the order of recruitment. An odd number in the envelope meant that the narrowband UVB was given on the right-hand side, and an even number that it was given on the left-hand side. Dermatologists at the Department of Dermatology were requested to recruit patients for the study. The sealed envelope was opened only after the patient had signed a form consenting to participation. The patients were monitored each time by the same masked investigator (ES 9 patients and TR 8 patients), who was not aware of the sides of randomization. If erythema appeared on either side, the masked investigator could ask to lower the dosing on that side, but all further instructions for the therapy were received from the unblinded author (TK).
Outcome measures. The severity of psoriasis was monitored using a modified PASI, where the palm, sole and head scores were neglected (19) . Another measure for improvement was a Global Improvement Score (GIS) with given semi-quantitative numerical scores: 21~deterioration, 0~no change, 1~minor improvement, 2~moderate improvement, 3~good improvement, 4~excellent to complete response. The third measure, a target lesion score (TLS), was used to assess two symmetric target lesions, one on each side of the body. Separate scores were given for erythema, scaling and thickness on a scale of 0 -8, where 0 indicated no symptoms and 8 was the worst possible condition. The TLS (range 0 -24) was the sum of sub-scores. A blinded observer recorded the status at the onset of the trial, and thereafter weekly up to 10 weeks, excluding week 1. The post-treatment follow-up visits were arranged at 2-month intervals maximally up to 6 months. If the result at the end of the treatment period was unsatisfactory, the patient was free to withdraw from the post-treatment follow-up.
Endpoints. The primary endpoint of the study was the recorded difference in the improvement at the end of interventions using the PASI, GIS and TLS. The secondary endpoint was the time to 100% relapse in the PASI or the time to start of another treatment recorded at 2-month intervals during the post-treatment phase.
Interventions
For the half-side irradiations, a half-body UV protective suit was prepared from double brown cotton material (20 . The final cumulative individual UV doses of the patients were corrected using these factors.
The initial UVB dose was 50% of the individual MED. The dose was incrementally increased each time by 20% or 30% until erythema appeared or a dose of 1.0 J/cm 2 was reached. Thereafter the dose was increased by 10% or 20%. If erythema developed the dose was kept constant, reduced, or not given. For PUVA, a standard commercial alcohol solution of trioxysalen 50 mg/100 ml (Tripsor1, Orion Corporation, Orion Pharma, Espoo, Finland) was diluted in 150 l of tap water to produce a standard 0.33 mg/l bath concentration. The bathing time was 10 min. For skin phototype II the initial dose was 0.05 J/cm 2 and each dose was applied at least three times. Increments were initially 20 -30%, and thereafter 10%. For phototypes III and IV the initial dose was slightly higher, 0.07 J/cm 2 , and each dose was repeated at least twice. The dose was reduced if mild erythema was detected, and if definite redness appeared PUVA was not given. After disappearance of psoriasis on either treatment side, that treatment was withdrawn, but the other was continued.
Patients were not allowed to pursue other anti-psoriasis treatments during the study. Salicylic acid (5%) in white petrolatum or emollient (Nutraderm1, Orion, Finland) could be used at home to reduce scaling and dryness of the skin, but these could not be applied before irradiations. An adverse event, like definite skin burn, could be alleviated with 1-or 2-day application of topical glucocorticoid formulation. Scalp and face psoriasis was excluded from the study evaluations, and topical treatment was allowed on these areas.
Statistical methods
The results were to be evaluated on intention to treat basis. Medians and ranges for the PASI, GIS and TLS scores are given. The statistical significance of difference in improvement was tested using the two-tailed Wilcoxon's signed ranks test with StatsDirect, Statistical Software (Version 1.9.5 -14.6.2001). No corrections were made for multiple comparisons. The median values and ranges for cumulative UVA and UVB doses, MEDs and MPDs are also given.
RESULTS

Primary endpoint
At the onset of the trial there were no significant differences in the PASI scores for the two treatments (Table II) . At the end of the treatment period the median PASI was 1.0 (range 0 -6.6) on the UVB TL01 side and 3.5 (0 -9.6) on the TMP bath PUVA side (Table II) . The difference was statistically highly significant (pv0.001). With UVB the relative decrease in the median PASI was 77% (range 24 -100%), and with PUVA 45% (range 28% to 100%). Five patients showed 100% PASI improvement after UVB and one patient after PUVA. UVB also improved psoriasis faster than PUVA (Fig. 2) , the difference between the treatments already being statistically significant at week 3 ( pv0.014).
Measured with the GIS, the clinical response was excellent in seven patients with UVB, but only in one patient with PUVA (Table III) . The difference in the improvement with the two treatments was also statistically highly significant, as shown in Table II . A statistically significant difference was already detected at week 3 (p~0.016) (data not shown). A similar result was obtained when the target lesions on each side were monitored. At the end of treatments, TLS of the UVBand PUVA-treated sides differed statistically significantly in favour of UVB (Table II) .
Secondary endpoints -relapses
After 30 treatments the result was unsatisfying in 2 of the 15 patients who completed the treatments. These two withdrew from the post-treatment follow-up (Table IV) , one showing a 93% improvement (PASI) with UVB but only 37% response with PUVA, and the other showing bilaterally only a 25% response to both treatments. Of the 13 patients who participated at the 2-month post-treatment follow-up visit (Table IV) , four had used other treatments, two showed a 100% PASI relapse bilaterally, and one patient displayed a 100% relapse on the PUVA side. At the 4-month visit two of six patients had not received other treatments, but the PASI score of these two indicated a bilateral 100% relapse.
UV doses and treatment numbers
The a Follow-up discontinued. *Includes two patients who failed to improve with PUVA. ranged from 0.88 to 2.2 J/cm 2 for skin phototype II, from 1.0 to 1.5 J/cm 2 for phototype III, and from 2.0 to 2.5 J/cm 2 for phototype IV. The UVA doses ranged from 0.15 to 0.4 J/cm 2 for skin phototype II, from 0.2 to 0.5 J/cm 2 for phototype III, and from 0.4 to 0.6 J/cm 2 for phototype IV. The median number of UVB TL01 treatments was 30 (range 22 -30) , identical to the number of UVA irradiations (range 23 -30), excluding only the two patients who withdrew early from the study (Table I) .
Adverse events
Erythema was recorded more frequently after UVB (17 times) than after PUVA (11 times). Definite erythema was detected nine times after UVB and only three times after PUVA. Two patients applied topical corticosteroid for the redness a total of three times, one patient applied corticosteroid twice and two further patients used it once on a restricted redness area.
DISCUSSION
We found that UVB TL01 improved psoriasis more effectively than TMP bath PUVA in 15 of 17 patients. Excellent 100% PASI and GIS remission was also achieved more frequently with UVB than PUVA (Table III) . The results are consistent with a recent study reporting clearance in 21 of 28 (75%) with TL01 and 15 of 28 (54%) with TMP bath PUVA (3). We do not consider that PUVA treatment was suboptimal in our study. A concentration of 0.33 mg/l is the most frequently used concentration in Finland, as is the 10-min time to bathe. Dawe et al. (3) used the same concentration and soaking time in their study. The only difference in the treatment protocols existed in the UVA dosing schedules. Despite this, the results were consistent. Erythema episodes occurred in both studies more often with TL01 than TMP PUVA and in both studies, treatment-related withdrawals were due to inadequate response with PUVA (3). Therefore the results from the two TMP bath PUVA vs TL01 studies must be contrasted against other PUVA regimens.
Dawe el al. (3) attempted to perform a meta-analysis of various PUVA protocols vs TL01 UVB, and found that the data could not be combined; there were too many differences between studies in regimens and in study design. Based on odds ratios and 95% confidence intervals, their results contrasted with previous studies that favoured PUVA (1, 3, 21, 22) . Recently, Markham et al. (2) reported that TL01 UVB used three times weekly was as effective as oral 8-MOP PUVA given twice weekly, confirming results of an earlier paired comparison study with 8-MOP oral PUVA and TL01 (23) . Thus, it seems that new data are accumulating to favour TL01 in contrast to oral 8-MOP PUVA regimens -the clinical results and also safety aspects favour TL01 (3). We found no direct comparison study with 8-MOP bath PUVA vs TL01, but the efficacy of 8-MOP bath delivery was earlier confirmed to be equal to that of oral 8-MOP PUVA (24, 25) . It is also possible that the weaker clearance of 63% with TL01 compared with 84% with PUVA could be due to a twice weekly treatment protocol of TL01 (22) .
Topical application of TMP or 8-MOP has been popular in Scandinavia, Finland and the UK for some decades, but TMP and 8-MOP bath PUVA have attracted worldwide interest only recently. However, in Finland the usage of TMP is declining and TL01 is given instead. Some years ago TMP bath PUVA was shown to be safe in the long term as regards the carcinogenic potential (14, 15) . We consider that the dangers of topical TMP are mainly associated with acute phototoxicity.
In earlier PUVA protocols the frequency of treatments ranged from 2 to 4 weekly, but now the twice a week protocol is used most frequently (1 -3, 20 -23) . After a single PUVA exposure erythema is maximal as late as at 72 -96 h (15, 16) . We agree that treatments given only twice a week help to avoid cumulative erythema. The discussion on the preference between the skin type-or MPD-based UVA dosing protocols seems to be mainly speculative for TMP bath PUVA due to uncertainty caused by the very short irradiation times. During the first exposures, the lamps are hardly all lit when they must be switched off again. Clearly, 8-MOP PUVA and TL01 differ from TMP bath PUVA in this respect, and this may be one explanation for the different results.
TL01 cleared psoriasis faster than PUVA, and the difference was clinically obvious at week 3, i.e. after eight treatments. In our study, the masking proved successful, because one blinded inspector suspected that they recognized the PUVA-treated side 'for its faster clearance and tanning' at week 3, although that side was in fact treated with TL01.
The need for increased UV dose and larger number of exposures may be a consequence of the monotherapy treatment protocol. In some patients the cumulative UVB dose grew high. The cumulative UVA doses received by patients ranged from 3.31 to 12.51 J/cm 2 , and exceeded the average UVA dose of 3.54 J/cm 2 (range 0.43 -19.14 J/cm 2 ; n~86) received by patients in our earlier study (26) . To keep the cumulative UV dose reasonable, we recommend treatment combinations for normal clinical practice.
Half-side comparison is prone to biases. It not only differs from normal clinical practice, as noted above, but it also involves a risk that the treatments will interfere with each other. 8-MOP DNA mono-adducts have been found to persist in skin longer than free psoralens, which means that subsequent UVA exposures might give an increased response relative to the first treatment (27, 28) . In view of this, we cannot exclude the possibility that small traces of TMP are absorbed and remain in skin for 48 h after repeated baths.
Although TMP plus UVB TL01 has not itself been investigated, two studies report systemic 8-MOP plus UVB TL01 to be as effective as 8-MOP PUVA, indicating that psoralens interact with TL01 (29, 30) . Furthermore, a study on the time course of photosensitivity following TMP bath PUVA revealed that pre-irradiated skin of patients remained photosensitive up to 48 h, in contrast to previously non-irradiated skin, which returned to normal within 24 h (16). In interpreting the results of a half-side comparison study, therefore, the possibility of interactions (TMP and TL01) cannot be completely excluded. Yet another bias may follow from systemic immunology responses after half-body treatments. In particular, high UV doses inducing erythema have been shown to induce the release of interleukin-10. Interactions between two UV treatments can be avoided only with separate treatment groups.
We conclude that, on a half-side comparison basis, narrowband UVB improved psoriasis clinically and statistically more efficiently than trimethylpsoralen bath PUVA, and UVB was better tolerated.
